STAAR Surgical (NASDAQ:STAA) Major Shareholder Broadwood Partners, L.P. Acquires 23,000 Shares

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. bought 23,000 shares of the stock in a transaction on Wednesday, December 18th. The shares were bought at an average cost of $24.33 per share, with a total value of $559,590.00. Following the purchase, the insider now owns 10,848,631 shares of the company’s stock, valued at $263,947,192.23. This trade represents a 0.21 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Monday, December 16th, Broadwood Partners, L.P. purchased 53,500 shares of STAAR Surgical stock. The stock was bought at an average cost of $24.24 per share, for a total transaction of $1,296,840.00.

STAAR Surgical Trading Down 4.6 %

Shares of NASDAQ STAA opened at $24.26 on Thursday. The stock has a market cap of $1.20 billion, a P/E ratio of 55.14 and a beta of 0.59. The business’s fifty day simple moving average is $28.43 and its 200-day simple moving average is $34.63. STAAR Surgical has a 12-month low of $23.72 and a 12-month high of $52.68.

Wall Street Analyst Weigh In

STAA has been the subject of several research reports. Stephens upgraded shares of STAAR Surgical to a “hold” rating in a report on Monday, December 2nd. Canaccord Genuity Group dropped their price objective on STAAR Surgical from $31.00 to $28.00 and set a “hold” rating for the company in a research note on Monday, December 9th. Stifel Nicolaus decreased their target price on STAAR Surgical from $50.00 to $44.00 and set a “buy” rating on the stock in a research note on Monday, August 26th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of STAAR Surgical in a research report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $42.83.

Institutional Investors Weigh In On STAAR Surgical

A number of hedge funds have recently bought and sold shares of the stock. SG Americas Securities LLC grew its position in shares of STAAR Surgical by 173.5% during the second quarter. SG Americas Securities LLC now owns 9,038 shares of the medical instruments supplier’s stock worth $430,000 after buying an additional 5,733 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in STAAR Surgical by 3.8% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 11,343 shares of the medical instruments supplier’s stock worth $540,000 after acquiring an additional 418 shares during the last quarter. Louisiana State Employees Retirement System grew its holdings in STAAR Surgical by 2.1% during the 2nd quarter. Louisiana State Employees Retirement System now owns 24,700 shares of the medical instruments supplier’s stock worth $1,176,000 after acquiring an additional 500 shares in the last quarter. Slow Capital Inc. increased its position in shares of STAAR Surgical by 3.1% in the 2nd quarter. Slow Capital Inc. now owns 67,649 shares of the medical instruments supplier’s stock valued at $3,221,000 after purchasing an additional 2,003 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in shares of STAAR Surgical by 1.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 405,222 shares of the medical instruments supplier’s stock valued at $19,293,000 after purchasing an additional 5,712 shares in the last quarter. Institutional investors and hedge funds own 96.70% of the company’s stock.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.